Spontaneous Bacterial Peritonitis
Conditions
Brief summary
AIM:- A randomized non-inferiority trial comparing low dose albumin versus standard dose albumin in high risk Spontaneous Bacterial Peritonitis. Methodology In this non-inferior randomized controlled trial one group will receive Low dose albumin: 20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours and other group will receive Standard dose albumin: 20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 h (duration of infusion 6 hours). Study population: Patients of age \> 18 years of age with cirrhosis of liver who are admitted in ward/Intensive Care Unit diagnosed with Spontaneous Bacterial Peritonitis. Study design: Randomized controlled trial Study period: September 2019- September 2020 Sample size: 300 (150 cases in each group) If there is a true difference in favour of the experimental treatment of 5 % then 270 patients are required to be 80% sure that the upper limit of a one sided 95% confidence interval (or equivalently a 90 % two-sided confidence interval) will exclude a difference in favour of the standard group of more than 5 %. And if the investigators consider 10% drop out final sample size is 270+30=300. 150 in each limb. Cases will be randomly allocated in 2 groups by block randomization method with block size taken as 10. Monitoring and assessment: all the parameters of the objective and also noted any adverse effects. Adverse Effects: Nausea, Vomiting, Fever with chills, dyspnea Stopping Rule: in the event of any of the adverse effects during therapy. Expected Outcome of the project: Proportion of patients having new development or progression of Acute Kidney Injury by day 7
Interventions
BIOLOGICALLow Dose Albumin
20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours
BIOLOGICALStandard dose Albumin
20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours (duration of infusion 6 hours).
Sponsors
Institute of Liver and Biliary Sciences, India
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. \>18 years of age 2. Cirrhosis with SBP (community acquired, health care associated and nosocomial) and baseline serum bilirubin ≥4 mg/dl and/or SCr ≥ 1 mg/dl.
Exclusion criteria
1. Antibiotic treatment within one week before the diagnosis of SBP (except for prophylactic treatment with norfloxacin) 2. Significant cardiac failure, pulmonary disease 3. Known CKD ( Chronic Kidney Disease)or findings suggestive of organic nephropathy (proteinuria, haematuria, or Abnormal findings on renal USG) 4. Hepatocellular carcinoma 5. HIV (Human Immunodeficiency Virus) infection; 6. GI (Gastrointestinal) bleed within 1 month before the study 7. Ileus 8. Grade 3 to 4 hepatic encephalopathy 9. Other types of infection 10. Shock 11. Presence of any potential causes of dehydration (such as diarrhoea or an intense response to diuretic treatment) within one week before the diagnosis of SBP). 12. Baseline serum bilirubin \<4 mg/dl or S. Cr \< 1 mg/dl 13. Serum creatinine level of \> 3.0 mg/dl.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients having new development or progression of Acute Kidney Injury in both groups | Day 7 |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with resolution of Spontaneous Bacterial Peritonitis in both groups | Day 7 |
| Changes in RRI (Renal Resistive Index) in both groups | Day 6 |
| Number of participants who will develop volume overload in both groups | Day 7 |
| Number of participants who will not survive in both groups. | Day 7 |
Countries
India
Outcome results
None listed